Drugs / Sacubitril/valsartan
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03760588 | Jan 2019 → Sep 2024 | female breast carcinoma, heart failure | Torbjorn Omland | Completed | Missed primary |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2018-08-25 | Novartis Pharmaceuticals | Novartis announces new data that show Entresto® (sacubitril/valsartan) can be initiated early & safely in hospitalized patients after an acute heart failure episode novartis.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sacubitril/valsartan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03760588 ↗ |
| Action | Inhibit | “contains a neprilysin inhibitor.” NCT03760588 ↗ |
| Route | Oral | “Sacubitril/valsartan (target dose 97/103 mg b.i.d.) and matching placebo will be provided orally” NCT03760588 ↗ |